Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rallybio (RLYB) EBIT (2023 - 2025)

Rallybio's EBIT history spans 3 years, with the latest figure at -$6.9 million for Q3 2025.

  • For Q3 2025, EBIT rose 42.61% year-over-year to -$6.9 million; the TTM value through Sep 2025 reached -$38.3 million, up 45.34%, while the annual FY2024 figure was -$60.5 million, 23.36% up from the prior year.
  • EBIT for Q3 2025 was -$6.9 million at Rallybio, up from -$10.1 million in the prior quarter.
  • Across five years, EBIT topped out at -$6.9 million in Q3 2025 and bottomed at -$21.1 million in Q4 2023.
  • The 3-year median for EBIT is -$17.0 million (2024), against an average of -$15.1 million.
  • The largest annual shift saw EBIT dropped 7.69% in 2024 before it soared 51.13% in 2025.
  • A 3-year view of EBIT shows it stood at -$21.1 million in 2023, then skyrocketed by 45.02% to -$11.6 million in 2024, then skyrocketed by 40.34% to -$6.9 million in 2025.
  • Per Business Quant, the three most recent readings for RLYB's EBIT are -$6.9 million (Q3 2025), -$10.1 million (Q2 2025), and -$9.7 million (Q1 2025).